Replimune (REPL) Cash from Investing Activities (2017 - 2026)
Replimune (REPL) posted Cash from Investing Activities of $86.5 million for Q1 2026, up 15.16% sequentially from $75.1 million in Q4 2025, and up 1223.45% YoY from $6.5 million in Q1 2025.
Analysis
Replimune (REPL) Cash from Investing Activities (2017 - 2026) Analysis & Trends
Replimune has reported Cash from Investing Activities for 10 years, with the latest figure at $86.5 million in Q1 2026.
- Quarterly Cash from Investing Activities rose 1223.45% year-over-year to $86.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $310.8 million (up 1406.28% YoY) and the FY2026 annual result came in at $310.8 million, up 1406.28% from the prior year.
- Cash from Investing Activities grew to $86.5 million in Q1 2026 per REPL's latest filing, from $75.1 million in the prior quarter.
- Over five years, Cash from Investing Activities peaked at $86.5 million in Q1 2026 and troughed at -$125.1 million in Q4 2022.
- A 5-year average of $14.0 million and a median of $7.4 million in 2023 frame the typical range for Cash from Investing Activities.
- The sharpest annual moves came in 2022 and 2023: Cash from Investing Activities plunged 832.2% in 2022, then jumped 35130.56% in 2023.
- Over 5 years, Cash from Investing Activities stood at -$125.1 million in 2022, then jumped by 143.13% to $54.0 million in 2023, then plunged by 185.85% to -$46.3 million in 2024, then surged by 262.18% to $75.1 million in 2025, then gained by 15.16% to $86.5 million in 2026.
- According to Business Quant data, Cash from Investing Activities over the past three periods registered $86.5 million, $75.1 million, and $84.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 329.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -1.66 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -49.35 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -363.46 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -229.72 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 24.51 Mn |
| 10 | Replimune | 1.46 Bn | 1.46 Bn | - | 49.99 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 49.99 Mn |
| Mar 31, 2026 | 86.51 Mn |
| Dec 31, 2025 | 75.12 Mn |
| Sep 30, 2025 | 84.17 Mn |
| Jun 30, 2025 | 65.05 Mn |
| Mar 31, 2025 | -7.70 Mn |
| Dec 31, 2024 | -46.32 Mn |
| Sep 30, 2024 | 458,000.00 |
| Jun 30, 2024 | 29.77 Mn |
| Mar 31, 2024 | 23.20 Mn |
| Dec 31, 2023 | 53.96 Mn |
| Sep 30, 2023 | 12.68 Mn |
| Jun 30, 2023 | 7.36 Mn |
| Mar 31, 2023 | -22.75 Mn |
| Dec 31, 2022 | -125.10 Mn |
| Sep 30, 2022 | 36,000.00 |
| Jun 30, 2022 | 5.32 Mn |
| Mar 31, 2022 | -4.33 Mn |
| Dec 31, 2021 | -13.42 Mn |
| Sep 30, 2021 | -11.05 Mn |